|
[1]MALINCHOC M, KAMATH PS, GORDON FD, et al.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts[J].Hepatology, 2000, 31 (4) :864-871.
|
|
[2]WIESNER R, EDWARDS E, FREEMAN R, et al.Model for end-stage liver disease (MELD) and allocation of donor livers[J].Gastroenterology, 2003, 124 (1) :91-96.
|
|
[3]WANG X, SARIN SK, NING Q.Definition of ACLF and inclusion criteria for extra-hepatic organ failure[J].Hepatol Int, 2015, 9 (3) :360-365.
|
|
[4]CHEN T, NING Q.Highlights of diagnosis and treatment for end stage of liver disease with infection[J].Chin J Clin Infect Dis, 2017, 10 (5) :389-393. (in Chinese) 陈韬, 宁琴.终末期肝病合并感染诊治的热点与难点[J].中华临床感染病杂志, 2017, 10 (5) :389-393.
|
|
[5]ARVANITI V, D'AMICO G, FEDE G, et al.Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J].Gastroenterology, 2010, 139 (4) :1246-1256, 1256 e1241-1245.
|
|
[6]JHA AK, NIJHAWAN S, SUCHISMITA A.Sepsis in acute on chronic liver failure[J].Dig Dis Sci, 2011, 56 (4) :1245-1246;author reply 1246.
|
|
[7]YANG L, WU T, LI J.Bacterial infections in acute-on-chronic liver failure[J].Semin Liver Dis, 2018, 38 (2) :121-133.
|
|
[8]European Assoliation for the study of the liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J].J Hepatol, 2018, 69 (2) :406-460.
|
|
[9]OEY RC, de MAN RA, ERLER NS, et al.Microbiology and antibiotic susceptibility patterns in spontaneous bacterial peritonitis:A study of two Dutch cohorts at a 10-year interval[J].United European Gastroenterol J, 2018, 6 (4) :614-621.
|
|
[10]NING NZ, LI T, ZHANG JL, et al.Clinical and bacteriological features and prognosis of ascitic fluid infection in Chinese patients with cirrhosis[J].BMC Infect Dis, 2018, 18 (1) :253.
|
|
[11]JALAN R, FERNANDEZ J, WIEST R, et al.Bacterial infections in cirrhosis:a position statement based on the EASL Special Conference 2013[J].J Hepatol, 2014, 60 (6) :1310-1324.
|
|
[12]KURUP A, LIAU KH, REN J, et al.Antibiotic management of complicated intra-abdominal infections in adults:The Asian perspective[J].Ann Med Surg (Lond) , 2014, 3 (3) :85-91.
|
|
[13]SOFJAN AK, MUSGROVE RJ, BEYDA ND, et al.Prevalence and predictors of spontaneous bacterial peritonitis due to ceftriaxone-resistant organisms at a large tertiary center in the United States[J].JGlob Antimicrob Resist, 2018.[Epub ahead of print]
|
|
[14]SALERNO F, BORZIO M, PEDICINO C, et al.The impact of infection by multidrug-resistant agents in patients with cirrhosis.Amulticenter prospective study[J].Liver Int, 2017, 37 (1) :71-79.
|
|
[15]SARIN SK, CHOUDHURY A.Acute-on-chronic liver failure:terminology, mechanisms and management[J].Nat Rev Gastroenterol Hepatol, 2016, 13 (3) :131-149.
|
|
[16]MARSDEN PA, NING Q, FUNG LS, et al.The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis[J].J Clin Invest, 2003, 112 (1) :58-66.
|
|
[17]WU Z, HAN M, CHEN T, et al.Acute liver failure:mechanisms of immune-mediated liver injury[J].Liver Int, 2010, 30 (6) :782-794.
|
|
[18]WANG X, NING Q.Immune mediated liver failure[J].EXCLI J, 2014, 13:1131-1144.
|
|
[19]WIEST R, KRAG A, GERBES A.Spontaneous bacterial peritonitis:recent guidelines and beyond[J].Gut, 2012, 61 (2) :297-310.
|
|
[20]MACINTOSH T.Emergency management of spontaneous bacterial peritonitis-A clinical review[J].Cureus, 2018, 10 (3) :e2253.
|
|
[21]HWANG SY, YU SJ, LEE JH, et al.Spontaneous fungal peritonitis:A severe complication in patients with advanced liver cirrhosis[J].Eur J Clin Microbiol Infect Dis, 2014, 33 (2) :259-264.
|
|
[22]LAHMER T, BRANDL A, RASCH S, et al.Fungal peritonitis:Underestimated disease in critically Ill patients with liver cirrhosis and spontaneous peritonitis[J].PLo S One, 2016, 11 (7) :e0158389.
|
|
[23]VAID U, KANE GC.Tuberculous peritonitis[J].Microbiol Spectr, 2017, 5 (1) :1-6.
|
|
[24]VAZ AM, PEIXE B, ORNELAS R, et al.Peritoneal tuberculosis as a cause of ascites in a patient with cirrhosis[J].BMJ Case Rep, 2017, 2017.
|
|
[25]HUANG HJ, YANG J, HUANG YC, et al.Diagnostic feature of tuberculous peritonitis in patients with cirrhosis:A matched casecontrol study[J].Exp Ther Med, 2014, 7 (4) :1028-1032.
|
|
[26]SHALIMAR, ROUT G, JADAUN SS, et al.Prevalence, predictors and impact of bacterial infection in acute on chronic liver failure patients[J].Dig Liver Dis, 2018.
|
|
[27]EL-AMIN H, SABRY AMM, AHMED RE, et al.Types and microbiological spectrum of infections in patients with cirrhosis:A single-centre experience in Upper Egypt[J].Arab J Gastroenterol, 2017, 18 (3) :159-164.
|
|
[28]CAI J, ZHANG M, HAN T, et al.Characteristics of infection and its impact on short-term outcome in patients with acute-onchronic liver failure[J].Medicine (Baltimore) , 2017, 96 (37) :e8057.
|
|
[29]PARK JW, LEE JK, LEE KT, et al.How to interpret the bile culture results of patients with biliary tract infections[J].Clin Res Hepatol Gastroenterol, 2014, 38 (3) :300-309.
|
|
[30]MUCKE MM, KESSEL J, MUCKE VT, et al.The role of Enterococcus spp.and multidrug-resistant bacteria causing pyogenic liver abscesses[J].BMC Infect Dis, 2017, 17 (1) :450.
|
|
[31]GOMEZ-HURTADO I, SUCH J, SANZ Y, et al.Gut microbiota-related complications in cirrhosis[J].World J Gastroenterol, 2014, 20 (42) :15624-15631.
|
|
[32]GIANNELLI V, DI GREGORIO V, IEBBA V, et al.Microbiota and the gut-liver axis:Bacterial translocation, inflammation and infection in cirrhosis[J].World J Gastroenterol, 2014, 20 (45) :16795-16810.
|
|
[33]NAVASA M, RODES J.Bacterial infections in cirrhosis[J].Liver Int, 2004, 24 (4) :277-280.
|
|
[34]BARTOLETTI M, GIANNELLA M, CARACENI P, et al.Epidemiology and outcomes of bloodstream infection in patients with cirrhosis[J].J Hepatol, 2014, 61 (1) :51-58.
|
|
[35]ZHAO H, GU X, ZHAO R, et al.Evaluation of prognostic scoring systems in liver cirrhosis patients with bloodstream infection[J].Medicine (Baltimore) , 2017, 96 (50) :e8844.
|
|
[36]XIE Y, TU B, ZHANG X, et al.Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection[J].Oncotarget, 2018, 9 (3) :3980-3995.
|
|
[37]XIE Y, TU B, XU Z, et al.Bacterial distributions and prognosis of bloodstream infections in patients with liver cirrhosis[J].Sci Rep, 2017, 7 (1) :11482.
|
|
[38]LIU BM, CHUNG KJ, CHEN CH, et al.Risk factors for the outcome of cirrhotic patients with soft tissue infections[J].J Clin Gastroenterol, 2008, 42 (3) :312-316.
|
|
[39]SU CM, CHANG WN, TSAI NW, et al.Clinical features and outcome of community-acquired bacterial meningitis in adult patients with liver cirrhosis[J].Am J Med Sci, 2010, 340 (6) :452-456.
|
|
[40]BARAHONA-GARRIDO J, HERNANDEZ-CALLEROS J, TELLEZ-AVILA FI, et al.Bacterial meningitis in cirrhotic patients:case series and description of the prognostic role of acute renal failure[J].J Clin Gastroenterol, 2010, 44 (9) :e218-223.
|
|
[41]PAGLIANO P, BOCCIA G, DE CARO F, et al.Bacterial meningitis complicating the course of liver cirrhosis[J].Infection, 2017, 45 (6) :795-800.
|
|
[42]EPSTEIN O, DICK R, SHERLOCK S.Prospective study of periostitis and finger clubbing in primary biliary cirrhosis and other forms of chronic liver disease[J].Gut, 1981, 22 (3) :203-206.
|
|
[43]ALLAIRE M, CADRANEL JD, BUREAU C, et al.Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis:A retrospective case-control study[J].Eur J Gastroenterol Hepatol, 2018.[Epub ahead of print]
|
|
[44]RUIZ-MORALES J, IVANOVA-GEORGIEVA R, FERNANDEZ-HIDALGO N, et al.Left-sided infective endocarditis in patients with liver cirrhosis[J].J Infect, 2015, 71 (6) :627-641.
|
|
[45]LEE S, UM T, JOE SG, et al.Changes in the clinical features and prognostic factors of endogenous endophthalmitis:fifteen years of clinical experience in Korea[J].Retina, 2012, 32 (5) :977-984.
|
|
[46]CHUNG KS, KIM YK, SONG YG, et al.Clinical review of endogenous endophthalmitis in Korea:A 14-year review of culture positive cases of two large hospitals[J].Yonsei Med J, 2011, 52 (4) :630-634.
|
|
[47]MOREAU R, JALAN R, GINES P, et al.Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis[J].Gastroenterology, 2013, 144 (7) :1426-1437, 1437 e1421-1429.
|
|
[48]FERNANDEZ J, GUSTOT T.Management of bacterial infections in cirrhosis[J].J Hepatol, 2012, 56 (Suppl 1) :s1-s12.
|
|
[49]GUSTOT T, DURAND F, LEBREC D, et al.Severe sepsis in cirrhosis[J].Hepatology, 2009, 50 (6) :2022-2033.
|
|
[50] MUELLER C, COMPHER C, ELLEN DM.A.S.P.E.N.clinical guidelines:Nutrition screening, assessment, and intervention in adults[J].JPEN J Parenter Enteral Nutr, 2011, 35 (1) :16-24.
|
|
[51]JENS KONDRUP, REMY MEIEr.Screening by NRS 2002 improves clinical outcome[J].Chin J Clin Nutr, 2013, 21 (3) :133-139. (in Chinese) 詹斯·康卓普, 雷米·梅耶.营养风险筛查NRS 2002改善临床结局[J].中华临床营养杂志.2013, 21 (3) :133-139.
|
|
[52]MONTANO-LOZA AJ, MEZA-JUNCO J, PRADO CM, et al.Muscle wasting is associated with mortality in patients with cirrhosis[J].Clin Gastroenterol Hepatol, 2012, 10 (2) :166-173, 173e161.
|
|
[53]HOLT EW, FREDERICK RT, VERHILLE MS.Prognostic value of muscle wasting in cirrhotic patients[J].Clin Gastroenterol Hepatol, 2012, 10 (9) :1056;author reply 1056-1057.
|
|
[54]CEDERHOLM T, BARAZZONI R, AUSTIN P, et al.ESPENguidelines on definitions and terminology of clinical nutrition[J].Clin Nutr, 2017, 36 (1) :49-64.
|
|
[55]CABRE E, RODRIGUEZ-IGLESIAS P, CABALLERIA J, et al.Short-and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition:a multicenter randomized trial[J].Hepatology, 2000, 32 (1) :36-42.
|
|
[56]PLAUTH M, CABRE E, CAMPILLO B, et al.ESPEN guidelines on parenteral nutrition:Hepatology[J].Clin Nutr, 2009, 28 (4) :436-444.
|
|
[57]PLANK LD, GANE EJ, PENG S, et al.Nocturnal nutritional supplementation improves total body protein status of patients with liver cirrhosis:A randomized 12-month trial[J].Hepatology, 2008, 48 (2) :557-566.
|
|
[58]NAKAYA Y, OKITA K, SUZUKI K, et al.BCAA-enriched snack improves nutritional state of cirrhosis[J].Nutrition, 2007, 23 (2) :113-120.
|
|
[59]MUTO Y, SATO S, WATANABE A, et al.Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis[J].Clin Gastroenterol Hepatol, 2005, 3 (7) :705-713.
|
|
[60]MARCHESINI G, BIANCHI G, MERLI M, et al.Nutritional supplementation with branched-chain amino acids in advanced cirrhosis:A double-blind, randomized trial[J].Gastroenterology, 2003, 124 (7) :1792-1801.
|
|
[61]SUN X, DUAN X, WANG C, et al.Protective effects of glycyrrhizic acid against non-alcoholic fatty liver disease in mice[J].Eur JPharmacol, 2017, 806:75-82.
|
|
[62]POLYAK SJ, FERENCI P, PAWLOTSKY JM.Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection[J].Hepatology, 2013, 57 (3) :1262-1271.
|
|
[63]FEDERICO A, DALLIO M, LOGUERCIO C.Silymarin/silybin and chronic liver disease:A marriage of many years[J].Molecules, 2017, 22 (2) .
|
|
[64] Chinese Society of Infectious Diseases, Chinese Medical Association.Expert consensus on liver inflammation and its prevention and treatment[J].Chin J Intect Dis, 2014, 23 (2) :65-75. (in Chinese) 中华医学会感染病学分会, 肝脏炎症及其防治专家共识专家委员会.肝脏炎症及其防治专家共识[J].中华传染病杂志, 2014, 32 (2) :65-75.
|
|
[65]SOLA E, SOLE C, GINES P.Management of uninfected and infected ascites in cirrhosis[J].Liver Int, 2016, 36 (Suppl 1) :109-115.
|
|
[66]PERICLEOUS M, SARNOWSKI A, MOORE A, et al.The clinical management of abdominal ascites, spontaneous bacterial peritonitis and hepatorenal syndrome:A review of current guidelines and recommendations[J].Eur J Gastroenterol Hepatol, 2016, 28 (3) :e10-18.
|
|
[67]CAMERINI R, GARACI E.Historical review of thymosin alpha 1 in infectious diseases[J].Expert Opin Biol Ther, 2015, 15 (Suppl1) :s117-s127.
|
|
[68]LI C, BO L, LIU Q, et al.Thymosin alpha1 based immunomodulatory therapy for sepsis:A systematic review and meta-analysis[J].Int J Infect Dis, 2015, 33:90-96.
|
|
[69]WU J, ZHOU L, LIU J, et al.The efficacy of thymosin alpha 1 for severe sepsis (ETASS) :A multicenter, single-blind, randomized and controlled trial[J].Crit Care, 2013, 17 (1) :R8.
|
|
[70]XU D, ZHAO M, SONG Y, et al.Novel insights in preventing gramnegative bacterial infection in cirrhotic patients:Review on the effects of GM-CSF in maintaining homeostasis of the immune system[J].Hepatol Int, 2015, 9 (1) :28-34.
|
|
[71]SHIOMI A, USUI T, ISHIKAWA Y, et al.GM-CSF but not IL-17 is critical for the development of severe interstitial lung disease in SKG mice[J].J Immunol, 2014, 193 (2) :849-859.
|
|
[72]KEDARISETTY CK, ANAND L, BHARDWAJ A, et al.Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis[J].Gastroenterology, 2015, 148 (7) :1362-1370.
|
|
[73]CHANSON P, PARIENTE A.Combination of granulocyte colonystimulating factor and erythropoietin in decompensated cirrhosis:a positive essay?[J].Rev Prat, 2015, 65 (4) :472-473.
|
|
[74]SHOUVAL D.The pros and cons of lamivudine vs.entecavir in decompensated or severe acute exacerbation of chronic hepatitis B[J].J Hepatol, 2014, 60 (6) :1108-1109.
|
|
[75]TERRAULT NA, BZOWEJ NH, CHANG KM, et al.AASLDguidelines for treatment of chronic hepatitis B[J].Hepatology, 2016, 63 (1) :261-283.
|
|
[76]AASLD/IDSA HCV Guidance Panel.Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|
|
[77]O'SHEA RS, DASARATHY S, MCCULLOUGH AJ.Alcoholic liver disease[J].Am J Gastroenterol, 2010, 105 (1) :14-32;quiz33.
|
|
[78]RUNYON BA.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology, 2013, 57 (4) :1651-1653.
|
|
[79]EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
|
|
[80]NANCHAL RS, AHMAD S.Infections in liver disease[J].Crit Care Clin, 2016, 32 (3) :411-424.
|
|
[81]SHI L, WU D, WEI L, et al.Nosocomial and community-acquired spontaneous bacterial peritonitis in patients with liver cirrhosis in China:Comparative microbiology and therapeutic implications[J].Sci Rep, 2017, 7:46025.
|
|
[82]QUAN J, ZHAO D, LIU L, et al.High prevalence of ESBL-producing Escherichia coli and Klebsiella pneumoniae in communityonset bloodstream infections in China[J].J Antimicrob Chemother, 2017, 72 (1) :273-280.
|
|
[83]DEVER JB, SHEIKH MY.Review article:Spontaneous bacterial peritonitis-bacteriology, diagnosis, treatment, risk factors and prevention[J].Aliment Pharmacol Ther, 2015, 41 (11) :1116-1131.
|
|
[84]FIORE M, LEONE S.Spontaneous fungal peritonitis:Epidemiology, current evidence and future prospective[J].World J Gastroenterol, 2016, 22 (34) :7742-7747.
|
|
[85]HASSAN EA, ABD EL-REHIM AS, HASSANY SM, et al.Fungal infection in patients with end-stage liver disease:low frequency or low index of suspicion[J].Int J Infect Dis, 2014, 23:69-74.
|
|
[86]FIORE M, ANDREANA L, LEONE S.Preemptive therapy of spontaneous fungal peritonitis[J].Hepatology, 2016, 64 (3) :997-998.
|
|
[87]BLUMBERG HM, BURMAN WJ, CHAISSON RE, et al.American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America:treatment of tuberculosis[J].Am J Respir Crit Care Med, 2003, 167 (4) :603-662.
|
|
[88]SANAI FM, BZEIZI KI.Systematic review:tuberculous peritonitispresenting features, diagnostic strategies and treatment[J].Aliment Pharmacol Ther, 2005, 22 (8) :685-700.
|
|
[89]SAIGAL S, AGARWAL SR, NANDEESH HP, et al.Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease:a preliminary report[J].J Gastroenterol Hepatol, 2001, 16 (9) :1028-1032.
|
|
[90]SARTELLI M, VIALE P, CATENA F, et al.2013 WSES guidelines for management of intra-abdominal infections[J].World J Emerg Surg, 2013, 8 (1) :3.
|
|
[91]AGUADO JM, SILVA JT, FERNANDEZ-RUIZ M, et al.Management of multidrug resistant Gram-negative bacilli infections in solid organ transplant recipients:SET/GESITRA-SEIMC/REIPI recommendations[J].Transplant Rev (Orlando) , 2018, 32 (1) :36-57.
|
|
[92]GOVINDAN S, HYZY RC.The 2016 Guidelines for hospital-acquired and ventilator-associated pneumonia.A selection correction?[J].Am J Respir Crit Care Med, 2016, 194 (6) :658-660.
|
|
[93]CHEN J, YANG Q, HUANG J, et al.Risk factors for invasive pulmonary aspergillosis and hospital mortality in acute-on-chronic liver failure patients:A retrospective-cohort study[J].Int J Med Sci, 2013, 10 (12) :1625-1631.
|
|
[94]ZHANG GQ, YAO YH, XU QP, et al.Analysis of microbial distribution and drug resistance of biliary tract infection[J].Exp Lab Med, 2008, 26 (5) :551-552. (in Chinese) 张国强, 姚艺辉, 许奇萍, 等.胆道感染微生物分布及菌株耐药性分析[J].实验与检验医学, 2008, 26 (5) :551-552.
|
|
[95]HAO CF, SUN LJ, LI ZL.Pathogens causing biliary tract infection and their sensitivity to antibiotics[J].Chin J Nosocomiol, 2011, 21 (1) :128-130. (in Chinese) 郝成飞, 孙兰菊, 李忠廉.胆道感染病原菌对抗菌药物的敏感性分析研究[J].中华医院感染学杂志, 2011, 21 (1) :128-130.
|
|
[96]FUKS D, COSSE C, REGIMBEAU JM.Antibiotic therapy in acute calculous cholecystitis[J].J Visc Surg, 2013, 150 (1) :3-8.
|
|
[97]de SANTIBANES M, GLINKA J, PELEGRINI P, et al.Extended antibiotic therapy versus placebo after laparoscopic cholecystectomy for mild and moderate acute calculous cholecystitis:A randomized double-blind clinical trial[J].Surgery, 2018.[Epub ahead of print]
|
|
[98]ANSALONI L, PISANO M, COCCOLINI F, et al.2016 WSESguidelines on acute calculous cholecystitis[J].World JEmerg Surg, 2016, 11:25.
|
|
[99]MOULOUDI E, MASSA E, PIPERIDOU M, et al.Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit:A 3-year study[J].Transplant Proc, 2014, 46 (9) :3219-3221.
|
|
[100]BARRETO R, ELIA C, SOLA E, et al.Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections[J].J Hepatol, 2014, 61 (1) :35-42.
|
|
[101]BAJAJ JS, O'LEARY JG, REDDY KR, et al.Second infections independently increase mortality in hospitalized patients with cirrhosis:The North American consortium for the study of end-stage liver disease (NACSELD) experience[J].Hepatology, 2012, 56 (6) :2328-2335.
|
|
[102]TOSHIKUNI N, UJIKE K, YANAGAWA T, et al.Candida albicans endophthalmitis after extracorporeal shock wave lithotripsy in a patient with liver cirrhosis[J].Intern Med, 2006, 45 (22) :1327-1332.
|
|
[103]ZHAO SJ, FU YQ, ZHU MX, et al.Patients of Escherichia coli bloodstream infection:Analysis of antibiotic resistance and predictors of mortality[J].Nation Med J China, 2017, 97 (32) :2496-2500. (in Chinese) 赵顺金, 符一骐, 祝茂仙, 等.大肠埃希菌血流感染患者耐药性及预后影响因素分析[J].中华医学杂志, 2017, 97 (32) :2496-2500.
|
|
[104]NELSON AN, JUSTO JA, BOOKSTAVER PB, et al.Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections[J].Infection, 2017, 45 (5) :613-620.
|
|
[105] PIOTROWSKI D, BORON-KACZMARSKA A.Bacterial infections and hepatic encephalopathy in liver cirrhosis-prophylaxis and treatment[J].Adv Med Sci, 2017, 62 (2) :345-356.
|
|
[106]HUANG KC, TSAI YH, LEE MS.Model for end-stage liver disease (MELD) score as a predictor and monitor of mortality in patients with vibrio vulnificus necrotizing skin and soft tissue infections[J].PLo S Negl Trop Dis, 2015, 9 (4) :e0003720.
|
|
[107] HE LX, XIAO YH, LU Q, et al.National antimicrobial treatment guidelines[M].People's Health Publishing House, 2012, Beijing. (in Chinese) 何礼贤, 肖永红, 陆权, 等.国家抗微生物治疗指南[M].人民卫生出版社, 2012, 北京.
|
|
[108]WU HS, WANG FD, TSENG CP, et al.Characteristics of healthcare-associated and community-acquired Klebsiella pneumoniae bacteremia in Taiwan[J].J Infect, 2012, 64 (2) :162-168.
|
|
[109]DORON SI, HIBBERD PL, GORBACH SL.Probiotics for prevention of antibiotic-associated diarrhea[J].J Clin Gastroenterol, 2008, 42 (Suppl 2) :s58-s63.
|
|
[110]KHEDIRI F, MRAD AI, AZZOUZ M, et al.Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults:A multicentre, randomized, double-blind, placebo-controlled, parallel group study[J].Gastroenterol Res Pract, 2011, 2011:783196.
|
|
[111]SURAWICZ CM, BRANDT LJ, BINION DG, et al.Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections[J].Am J Gastroenterol, 2013, 108 (4) :478-498;quiz499.
|
|
[112]MOORE JE, BARTON MD, BLAIR IS, et al.The epidemiology of antibiotic resistance in Campylobacter[J].Microbes Infect, 2006, 8 (7) :1955-1966.
|
|
[113]NEGRI M, SILVA S, HENRIQUES M, et al.Insights into Candida tropicalis nosocomial infections and virulence factors[J].Eur JClin Microbiol Infect Dis, 2012, 31 (7) :1399-1412.
|
|
[114]PENA MA, HORGA JF, ZAPATER P.Variations of pharmacokinetics of drugs in patients with cirrhosis[J].Expert Rev Clin Pharmacol, 2016, 9 (3) :441-458.
|
|
[115]HALILOVIC J, HEINTZ BH.Antibiotic dosing in cirrhosis[J].Am JHealth Syst Pharm, 2014, 71 (19) :1621-1634.
|
|
[116]ANDRADE RJ, TULKENS PM.Hepatic safety of antibiotics used in primary care[J].J Antimicrob Chemother, 2011, 66 (7) :1431-1446.
|
|
[117]LAN P, WANG SJ, SHI QC, et al.Comparison of the predictive value of scoring systems on the prognosis of cirrhotic patients with suspected infection[J].Medicine (Baltimore) , 2018, 97 (28) :e11421.
|
|
[118]WONG-BERINGER A, KRIENGKAUYKIAT J.Systemic antifungal therapy:new options, new challenges[J].Pharmacotherapy, 2003, 23 (11) :1441-1462.
|
|
[119]CHANG Y, BURCKART GJ, LESKO LJ, et al.Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels[J].J Clin Pharmacol, 2013, 53 (9) :962-966.
|
|
[120]CHEN Y, JI F, GUO J, et al.Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology[J].Sci Rep, 2016, 6:34055.
|
|
[121]LING Z, LIU X, CHENG Y, et al.Blood microbiota as a potential noninvasive diagnostic biomarker for liver fibrosis in severely obese patients:Choose carefully[J].Hepatology, 2017, 65 (5) :1775-1776.
|
|
[122]PANDE C, KUMAR A, SARIN SK.Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis:A double-blind placebo-controlled randomized-controlled trial[J].Eur J Gastroenterol Hepatol, 2012, 24 (7) :831-839.
|
|
[123]CORDOBA J, VENTURA-COTS M, SIMON-TALERO M, et al.Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF) [J].J Hepatol, 2014, 60 (2) :275-281.
|
|
[124]VICTOR DW, 3rd, QUIGLEY EM.Microbial therapy in liver disease:probiotics probe the microbiome-gut-liver-brain axis[J].Gastroenterology, 2014, 147 (6) :1216-1218.
|
|
[125]ZHOU F, PENG Z, MURUGAN R, et al.Blood purification and mortality in sepsis:A meta-analysis of randomized trials[J].Crit Care Med, 2013, 41 (9) :2209-2220.
|
|
[126]RIMMELE T, KELLUM JA.Clinical review:Blood purification for sepsis[J].Crit Care, 2011, 15 (1) :205.
|
|
[127]RONCO C, TETTA C, MARIANO F, et al.Interpreting the mechanisms of continuous renal replacement therapy in sepsis:The peak concentration hypothesis[J].Artif Organs, 2003, 27 (9) :792-801.
|
|
[128]MOOKERJEE RP.Prognosis and biomarkers in acute-on-chronic liver failure[J].Semin Liver Dis, 2016, 36 (2) :127-132.
|
|
[129]REDDY SS, CIVAN JM.From Child-Pugh to model for end-stage liver disease:Deciding who needs a liver transplant[J].Med Clin North Am, 2016, 100 (3) :449-464.
|
|
[130]NEMES B, GAMAN G, POLAK WG, et al.Extended-criteria donors in liver transplantation Part II:Reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation[J].Expert Rev Gastroenterol Hepatol, 2016, 10 (7) :841-859.
|
|
[131]OU P, CHEN Y, LI B, et al.Causes, clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital[J].Springerplus, 2015, 4:802.
|
|
[132]MCPHAIL MJ, FARNE H, SENVAR N, et al.Ability of King's college criteria and model for end-stage liver disease scores to predict mortality of patients with acute liver failure:A meta-analysis[J].Clin Gastroenterol Hepatol, 2016, 14 (4) :516-525 e515;quiz e543-e545.
|
|
[133]WANG J, MA K, HAN M, et al.Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure:Validation of the TPPM model[J].Hepatol Int, 2014, 8 (1) :64-71.
|
|
[134]MA K, GUO W, HAN M, et al.Entecavir treatment prevents disease progression in hepatitis B virus-related acute-on-chronic liver failure:Establishment of a novel logistical regression model[J].Hepatol Int, 2012, 6 (4) :735-743.
|
|
[135]CHOUDHURY A, KUMAR M, SHARMA BC, et al.Systemic inflammatory response syndrome in acute-on-chronic liver failure:Relevance of'golden window':A prospective study[J].J Gastroenterol Hepatol, 2017, 32 (12) :1989-1997.
|
|
[136]HERNAEZ R, SOLA E, MOREAU R, et al.Acute-on-chronic liver failure:an update[J].Gut, 2017, 66 (3) :541-553.
|
|
[137]BERNSMEIER C, SINGANAYAGAM A, PATEL VC, et al.Immunotherapy in the treatment and prevention of infection in acuteon-chronic liver failure[J].Immunotherapy, 2015, 7 (6) :641-654.
|
|
[138]WASMUTH HE, KUNZ D, YAGMUR E, et al.Patients with acute on chronic liver failure display"sepsis-like"immune paralysis[J].J Hepatol, 2005, 42 (2) :195-201.
|
DownLoad: